TRACON Pharmaceuticals (TCON) Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" TCON shares.
View TCON analyst ratings or view top-rated stocks.

1 Wall Street analysts have issued 1-year target prices for TRACON Pharmaceuticals' shares. Their TCON share price forecasts range from $3.00 to $12.00. On average, they anticipate the company's share price to reach $7.33 in the next twelve months. This suggests a possible upside of 1,086.6% from the stock's current price.
View analysts price targets for TCON or view top-rated stocks among Wall Street analysts.

TRACON Pharmaceuticals' stock was trading at $1.49 at the beginning of the year. Since then, TCON stock has decreased by 58.5% and is now trading at $0.6180.
View the best growth stocks for 2023 here.

TRACON Pharmaceuticals saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 161,000 shares, a decrease of 38.7% from the April 30th total of 262,500 shares. Based on an average daily trading volume, of 181,900 shares, the days-to-cover ratio is currently 0.9 days.
View TRACON Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our TCON earnings forecast.

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) released its quarterly earnings data on Wednesday, March, 8th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.03.

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX).

(TCON) raised $47 million in an IPO on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

TRACON Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.71%), Susquehanna International Group LLP (0.17%), Charles Schwab Investment Management Inc. (0.10%), Jane Street Group LLC (0.07%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc, Saundra L Pelletier and Scott B Brown.
View institutional ownership trends.

Shares of TCON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TCON stock can currently be purchased for approximately $0.62.

TRACON Pharmaceuticals (NASDAQ:TCON) has a market capitalization of $15.29 million and generates $350,000.00 in revenue each year. The biopharmaceutical company earns $-29,140,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis.

TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The official website for the company is www.traconpharma.com. The biopharmaceutical company can be reached via phone at (858) 550-0780, via email at ir@traconpharma.com, or via fax at 858-550-0786.